pulmonar

Un guiño para la trombólisis guiada por Catéter en tromboembolismo pulmonar

Catheter-Based Therapy for Pulmonary Embolism: Lower Mortality and Rehospitalization?

Venous thromboembolism represents one of the main causes of cardiovascular death. Pulmonary embolism (PE) can vary from asymptomatic to manifesting with shock and sudden death, with a wide clinical spectrum. Patient followup is crucial, seeing as survival PE patients usually experience residual symptoms at long term, such as dyspnea or functional capacity deterioration.&nbsp; For decades,<a href="https://solaci.org/en/2024/05/13/catheter-based-therapy-for-pulmonary-embolism-lower-mortality-and-rehospitalization/" title="Read more" >...</a>

Seguridad de combinar los nuevos anticoagulantes y la doble antiagregación

Acute Pulmonary Thromboembolism: When Anticoagulation Alone May Not Be Enough

In recent times, pulmonary thromboembolism (PTE) has been the subject of growing research due to its persistent impact on morbidity and mortality. Acute PTE, if not properly treated or inadequately treated, can lead to a debilitating condition known as post-PTE syndrome, which has been documented in nearly 50% of survivors. The primary treatment strategy for<a href="https://solaci.org/en/2023/11/08/acute-pulmonary-thromboembolism-when-anticoagulation-alone-may-not-be-enough/" title="Read more" >...</a>

Un guiño para la trombólisis guiada por Catéter en tromboembolismo pulmonar

FLAME Study: FlowTriever Device in High-Risk Pulmonary Embolism

High-risk pulmonary embolism (HR-PE) is characterized by hemodynamic instability and marked deformation of the right ventricular (RV) fiber, which can lead to acute RV failure and hemodynamic collapse, with in-hospital mortality close to 25%. While guidelines recommend anticoagulant treatment followed by thrombolytics, these strategy carries a high risk of bleeding and is not suitable for<a href="https://solaci.org/en/2023/10/24/flame-study-flowtriever-device-in-high-risk-pulmonary-embolism/" title="Read more" >...</a>

Impacto negativo de la hipertensión pulmonar en el TAVI

Have Complications Related to Balloon Pulmonary Angioplasty Changed Since its Inception?

Balloon pulmonary angioplasty: Evolution over time and its complications Balloon pulmonary angioplasty (BPA) has grown from its beginnings as an indication for patients with chronic thromboembolic pulmonary hypertension (CTEPH) to being currently a class 1 indication for inoperable patients and/or residual CTEPH. Current evidence on this topic is underpowered, as most reports are based on<a href="https://solaci.org/en/2023/04/11/have-complications-related-to-balloon-pulmonary-angioplasty-changed-since-its-inception/" title="Read more" >...</a>

Inflamación crónica, enfermedad coronaria y cáncer: distintas caras de una misma moneda

Pulmonary Artery Denervation: Valid Alternative for Pulmonary Arterial Hypertension Grade 1?

Pulmonary vessels are densely innervated by sympathetic, parasympathetic, and sensitive fibers.&nbsp; According to the World Health Organization (WHO) pulmonary arterial hypertension (PAH) grade 1 consists of obliterating pulmonary vascular remodeling accompanied by a diminished generation of vessel dilators.&nbsp;&nbsp; Its pharmacological treatment has certain limitations and sympathetic pulmonary vascular denervation might be a valid treatment alternative,<a href="https://solaci.org/en/2022/12/14/pulmonary-artery-denervation-valid-alternative-for-pulmonary-arterial-hypertension-grade-1/" title="Read more" >...</a>

Top